CL2009000322A1 - Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros. - Google Patents
Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros.Info
- Publication number
- CL2009000322A1 CL2009000322A1 CL2009000322A CL2009000322A CL2009000322A1 CL 2009000322 A1 CL2009000322 A1 CL 2009000322A1 CL 2009000322 A CL2009000322 A CL 2009000322A CL 2009000322 A CL2009000322 A CL 2009000322A CL 2009000322 A1 CL2009000322 A1 CL 2009000322A1
- Authority
- CL
- Chile
- Prior art keywords
- disorders
- composition
- pharmaceutical
- flibanserin
- sleep
- Prior art date
Links
- 208000019022 Mood disease Diseases 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 title abstract 2
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002053 flibanserin Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 2
- 208000012201 sexual and gender identity disease Diseases 0.000 title abstract 2
- 208000015891 sexual disease Diseases 0.000 title abstract 2
- 208000019116 sleep disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composición farmacéutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmacéutico de liberación que comprende esta composición, método para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08101599A EP2090297A1 (en) | 2008-02-13 | 2008-02-13 | Formulations of flibanserin |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000322A1 true CL2009000322A1 (es) | 2010-03-05 |
Family
ID=39431170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000322A CL2009000322A1 (es) | 2008-02-13 | 2009-02-12 | Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros. |
Country Status (13)
Country | Link |
---|---|
US (3) | US20110045090A1 (es) |
EP (2) | EP2090297A1 (es) |
JP (1) | JP2011511818A (es) |
CN (1) | CN101951894A (es) |
AR (1) | AR070367A1 (es) |
BR (1) | BRPI0908455A2 (es) |
CA (1) | CA2714542A1 (es) |
CL (1) | CL2009000322A1 (es) |
IL (1) | IL206577A0 (es) |
MX (1) | MX2010008852A (es) |
PE (1) | PE20091418A1 (es) |
TW (1) | TW200940057A (es) |
WO (1) | WO2009100886A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120301541A1 (en) * | 2011-05-24 | 2012-11-29 | Haronsky Elina | Compressed core for pharmaceutical composition |
UY36140A (es) | 2014-05-29 | 2016-01-08 | Novartis Ag | Formulación de ceritinib |
CN104926734B (zh) * | 2015-07-07 | 2017-04-05 | 苏州立新制药有限公司 | 氟班色林的制备方法 |
WO2017026950A1 (en) * | 2015-08-07 | 2017-02-16 | Santa Farma Ilac San. A. S. | Controlled release propiverine formulations |
WO2017055935A1 (en) * | 2015-09-30 | 2017-04-06 | Symed Labs Limited | Amorphous co-precipitates of flibanserin |
CN106866546A (zh) * | 2015-12-10 | 2017-06-20 | 常州爱诺新睿医药技术有限公司 | 氟班色林或其药学上可接受的盐与药用辅料的固体分散体及其制备方法 |
CN110251475B (zh) * | 2019-07-25 | 2021-07-16 | 沈阳信康药物研究有限公司 | 一种帕利哌酮片剂及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1251144B (it) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
DE19961334A1 (de) * | 1999-12-17 | 2001-06-21 | Roehm Gmbh | Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere |
MXPA04000913A (es) | 2001-08-02 | 2004-10-27 | Bidachem Spa | Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos. |
DE10209982A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
EA007185B1 (ru) * | 2002-05-22 | 2006-08-25 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а |
AU2005266459A1 (en) * | 2004-07-29 | 2006-02-02 | Sanofi-Aventis | Pharmaceutical multilayer tablet for controlled release of active ingredients with highly pH-dependent solubility |
WO2007002597A2 (en) * | 2005-06-27 | 2007-01-04 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
FR2887455B1 (fr) * | 2005-06-28 | 2007-08-10 | Sanofi Aventis Sa | Formulation a liberation prolongee de principes actifs de medicaments |
EP1940357A2 (en) * | 2005-09-30 | 2008-07-09 | SmithKline Beecham Corporation | Pharmaceutical compositions |
EP2363117B1 (en) * | 2006-01-27 | 2015-08-19 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids |
AR062320A1 (es) * | 2006-08-14 | 2008-10-29 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas |
CN104721168A (zh) * | 2006-08-25 | 2015-06-24 | 贝林格尔·英格海姆国际有限公司 | 控制释放系统及其制造方法 |
US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
-
2008
- 2008-02-13 EP EP08101599A patent/EP2090297A1/en not_active Withdrawn
-
2009
- 2009-02-11 PE PE2009000195A patent/PE20091418A1/es not_active Application Discontinuation
- 2009-02-11 EP EP09709701A patent/EP2252270A2/en not_active Withdrawn
- 2009-02-11 CN CN2009801052034A patent/CN101951894A/zh active Pending
- 2009-02-11 MX MX2010008852A patent/MX2010008852A/es not_active Application Discontinuation
- 2009-02-11 WO PCT/EP2009/000941 patent/WO2009100886A2/en active Application Filing
- 2009-02-11 US US12/867,097 patent/US20110045090A1/en not_active Abandoned
- 2009-02-11 BR BRPI0908455A patent/BRPI0908455A2/pt not_active IP Right Cessation
- 2009-02-11 CA CA2714542A patent/CA2714542A1/en not_active Abandoned
- 2009-02-11 JP JP2010546257A patent/JP2011511818A/ja active Pending
- 2009-02-12 CL CL2009000322A patent/CL2009000322A1/es unknown
- 2009-02-12 TW TW098104529A patent/TW200940057A/zh unknown
- 2009-02-12 AR ARP090100504A patent/AR070367A1/es unknown
-
2010
- 2010-06-23 IL IL206577A patent/IL206577A0/en unknown
-
2012
- 2012-10-22 US US13/657,147 patent/US20130209519A1/en not_active Abandoned
-
2014
- 2014-12-15 US US14/570,467 patent/US20150224058A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200940057A (en) | 2009-10-01 |
BRPI0908455A2 (pt) | 2015-12-15 |
PE20091418A1 (es) | 2009-10-07 |
EP2090297A1 (en) | 2009-08-19 |
IL206577A0 (en) | 2010-12-30 |
US20130209519A1 (en) | 2013-08-15 |
US20150224058A1 (en) | 2015-08-13 |
JP2011511818A (ja) | 2011-04-14 |
WO2009100886A2 (en) | 2009-08-20 |
EP2252270A2 (en) | 2010-11-24 |
AR070367A1 (es) | 2010-03-31 |
CN101951894A (zh) | 2011-01-19 |
MX2010008852A (es) | 2010-09-24 |
US20110045090A1 (en) | 2011-02-24 |
CA2714542A1 (en) | 2009-08-20 |
WO2009100886A3 (en) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000322A1 (es) | Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros. | |
CL2007002356A1 (es) | Sistema de liberacion farmaceutica que comprende flibanserina y por lo menos un excipiente farmaceuticamentre aceptable; y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, del sueno y sexuales, entre otros. | |
AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
CO6280490A2 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
CL2011000101A1 (es) | Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas. | |
AR060880A1 (es) | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual | |
CL2008003578A1 (es) | Compuestos derivados de imidazo[1,5-a]-quinoxalina, inhibidores pde10; composicion farmaceutica que los comprende y/o kit; procedimiento de preparacion de estos; y su uso en el tratamiento de enfermedades snc | |
UY28933A1 (es) | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos | |
BRPI1016147A2 (pt) | sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino | |
AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
CL2007001731A1 (es) | Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras. | |
PE20180399A1 (es) | Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas | |
CL2007001732A1 (es) | Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras. | |
MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
HN2011003011A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
AR060786A1 (es) | Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
CL2012002540A1 (es) | Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. | |
CO6341543A2 (es) | Composiciones mucoadherentes y sus usos | |
CL2008002545A1 (es) | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. | |
CL2009001077A1 (es) | Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo. | |
DOP2009000207A (es) | Nueva forma de dosificación | |
CL2009000876A1 (es) | Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno. |